Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: a case-control study

Endocrine. 2017 Apr;56(1):208-211. doi: 10.1007/s12020-016-1112-5. Epub 2016 Sep 14.


Fetuin is an endogenous inhibitor of the insulin receptor tyrosine kinase. Recent studies supported the possible role of fetuin B in metabolic diseases. This study is to evaluate the role of serum fetuin B in nonalcoholic fatty liver disease (NAFLD). A hospital-based case-control study of 184 subjects was conducted. Serum level of fetuin B was measured by enzyme-linked immunosorbent assay. The serum level of fetuin B in the control (91.0 ± 36.9 μg/ml) was lower than it in NAFLD (108.7 ± 38.5 μg/ml, P < 0.001). The percentage of NAFLD increased (42.9%, 58.7% and 60.2%; P < 0.001; linear-by-linear association: P < 0.001), as fetuin B concentration elevated in its tertiles, after adjustment of body mass index (BMI). Furthermore, compared with the 1st tertile, the 3rd tertile of fetuin B indicated an association with the presence of NAFLD (adjusted odds ratio = 2.087, 95% confidence interval [1.016 - 3.937], P = 0.023), after controlling age, sex, BMI, diabetes, hypertension and hypertriglyceridemia. Lastly, fetuin B correlated with diastolic blood pressure, serum alanine transaminase and triglycerides, among the controls. It suggested a potential association between serum fetuin B and the presence of NAFLD.

Keywords: case-control; fetuin B; hepatokine; nonalcoholic fatty liver disease.

MeSH terms

  • Aged
  • Alanine Transaminase / blood
  • Blood Pressure / physiology
  • Case-Control Studies
  • Cross-Sectional Studies
  • Female
  • Fetuin-B / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / blood*
  • Triglycerides / blood


  • Fetuin-B
  • Triglycerides
  • Alanine Transaminase